Letaplimab

• UNSPSC Description:

  Letaplimab (IBI-188) is a human IgG4 anti-CD47 monoclonal antibody. CD47 is overexpressed on cancer cells, it is a ligand for SIRPα. Letaplimab enhances tumor cell phagocytosis[1].

• Target Antigen:

  Others

• Type:

  Inhibitory Antibodies

• Related Pathways:

  Others

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/letaplimab.html

• Purity:

  95.00

• Solubility:

  10 mM in DMSO

• Smiles:

  [Letaplimab]

• References & Citations:

  [1]Miao Miao, et al. A Phase 1b Study to Evaluate Safety and Efficacy of IBI188 in Combination with Azacitidine (AZA) As a First-Line Treatment in Subjects with Newly Diagnosed Higher Risk Myelodysplastic Syndrome. MYELODYSPLASTIC SYNDROMES-CLINICAL AND EPIDEMIOLOGICAL NOVEMBER 15, 2022.

• Shipping Conditions:

  Dry Ice

• Storage Conditions:

  Store at -80°C for 2 years

• Clinical Information:

  Phase 2

• CAS Number:

  2283356-07-8